FDAãªü¯÷®üÀq¯g·sÃıÀ¥X
¬ü°ê¹«~¤ÎÃĪ«ºÞ²z§½(FDA)«e¤é(6¤é)§åã¥Ñ¬ü°ê¦Ê°·(Biogen)©M¤é¥»½Ãªö»sÃÄ(Eisai)¦X§@¬ãµoªºªü¯÷®üÀq¯g·sÃÄLeqembi(¤SºÙlecanemab)±À¥X¡A¥Î©óÓV´î»´«×©M¦´Áªü¯÷®üÀq¯g±wªÌªº»{ª¾¯à¤O¤U°³t«×¡C
Leqembi¥Dn³z¹L²¾°£±wªÌ¤j¸£¤¤ªº£]Ãþ¾ý¯»³J¥Õ(amyloid beta)´î½w¯f±¡´c¤Æ¡A¦¹«e´X¥G©Ò¦³¨Ï¥Î¦P¼ËªvÀø¤è¦¡ªº¹êÅç©ÊÃĪ«§¡Ãҹꥢ±Ñ¡C
¬ã¨s¤Hû¥h¦~9¤ëµoªíªì¨B¼Æ¾Ú¡AÅã¥ÜLeqembi¯à¨Ï±wªÌ»{ª¾¯à¤O°I°h³t«×´îºC27%¡A±©11¤ëµo¥¬ªº§¹¾ãÁ{þH¹êÅç¼Æ¾Ú¡A«o¥O¤HÃöª`³¡¤À±wªÌ¦³¥X¦å¤Î¸£¸~µÈªº°Æ§@¥Î¡C½Ãªöªí¥Ü¡ALecanemabªºªvÀø©w»ù¬°¨C¦~2.65¸U¬ü¤¸¡A¨Ãp¹ºµy«á¦b¤é¥»©M¼Ú¬w¥Ó½Ð¤W¥«³\¥i¡C(¸ô³zªÀ/ªk·sªÀ)